Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161449 | 0.88 | CASP2 (0.46) | BCHEFUCA1EPHX1SPHK2SPHK1 | |
| SCHEMBL21342122 | 0.80 | THRB (0.33) | ALDH1A1LMNAGAAPYGB | |
| SCHEMBL21342381 | 0.77 | — | — | |
| SCHEMBL22757339 | 0.76 | THRB (0.33) | ALDH1A1LMNA | |
| SCHEMBL20161691 | 0.74 | FUCA1 (0.42) | BCHEFUCA1MCL1GAAPYGB | |
| SCHEMBL20161703 | 0.74 | PYGB (0.51) | FUCA1GAAPYGB | |
| SCHEMBL10015241 | 0.73 | THRB (0.32) | FUCA1LMNASPHK2SPHK1 | |
| SCHEMBL1900467 | 0.73 | THRB (0.32) | FUCA1LMNASPHK2SPHK1 | |
| SCHEMBL16994826 | 0.73 | THRB (0.32) | FUCA1LMNASPHK2SPHK1 | |
| SCHEMBL3294716 | 0.73 | THRB (0.32) | FUCA1LMNASPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | BCHE 943/4885FUCA1 58/4885MCL1 4443/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | BCHE 943/4885FUCA1 58/4885MCL1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.